SURVYR

PODD

Insulet Corporation
$142.62
−$0.02 (0.01%)Oct 21 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-61%-42%-22%-2%+17%Oct 2025Oct 2026Apr 202652w high $354.8852w low $126.40
PODDSPY
Wall St. Highest PT $215.00 (+50.8%) Wall St. Avg PT $167.17 (+17.2%)
$130$184$238$292$346POC $154Hi $215Avg $167
Underwater Drawdown %Max DD -62.3%Current -58.8%
0.0%-62.3%
Relative Strength vs SPY-72.8% vs SPYUnderperforming
+88%0%-88%
1W
+$8.69 (6.49%)
1M
+$2.09 (1.49%)
3M
−$16.31 (10.26%)
6M
−$51.00 (26.34%)
YTD
−$141.62 (49.82%)
1Y
−$186.35 (56.65%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
23 analysts · mean score 2.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$142.62
Average target$167.17
+$24.55 (+17.2%) upsideaverage target vs current price
CurrentAverageMedian
Low$143.00
Median$167.17
High$215.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-12 · Jefferies reiterated Buy on PODD
Initiated
2026-10-07 · Barclays started covering PODD at Equal-Weight
Reiterated
2026-08-06 · Canaccord Genuity reiterated Buy on PODD
Downgrade
2026-08-06 · Leerink Partners downgraded PODD from Outperform to Market Perform
Reiterated
2026-08-06 · TD Cowen reiterated Hold on PODD
Reiterated
2026-08-06 · UBS reiterated Neutral on PODD
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$10.3B
P/E (last 12 months)27.7
P/E (next 12 months, estimated)19.3
52-week range$126.40 – $354.88
Revenue growth (latest quarter vs a year ago)+23.5%
Dividend yieldNo dividend
Analyst consensusBuy (23)
Average analyst price target$167.17 (+17%)

What they do

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
1st percentile in sector
F
12-1 return: -58.3%
Percentile within its GICS sector across the S&P 1500.
Growth
83rd percentile in sector
A-
Revenue growth (YoY): +23.5%
Percentile within its GICS sector across the S&P 1500.
Value
46th percentile in sector
C
Forward E/P: 5.5% · EBITDA/EV: 6.0%
Percentile within its GICS sector across the S&P 1500.
Profitability
74th percentile in sector
B+
Profit margin: +12.3% · Return on equity: +26.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 496 of 499 · 12-month momentum -51.9%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

PODD earningsNext report in 7 days
Next report · quarter Sep 2026
Wed Nov 4, 2026Before the open
EPS consensus$1.59 range $1.50–$1.66
Revenue consensus$832.6M 23 analysts
Last 4 quarters · EPS vs estimate
Aug 5, 2026$1.66est $1.45+14.3%Above estimates
May 6, 2026$1.42est $1.19+19.3%Above estimates
Feb 18, 2026$1.55est $1.46+6.0%Above estimates
Nov 6, 2025$1.24est $1.15+8.1%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-23 23:44:30 ET
24-1125-0225-0525-0825-1126-0226-0526-080.001.66
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$801.7M+23.5%
2026-03-31$761.7M–
2025-12-31$783.8M–
2025-09-30$706.3M–
2025-06-30$649.1M–

News & catalysts

More news
Align Technology Takes Over #479 Spot From Insulet
Nasdaq · Oct 21
Rating changes
Reiterated
2026-10-12 · Jefferies reiterated Buy on PODD
Initiated
2026-10-07 · Barclays started covering PODD at Equal-Weight
Reiterated
2026-08-06 · Canaccord Genuity reiterated Buy on PODD
Downgrade
2026-08-06 · Leerink Partners downgraded PODD from Outperform to Market Perform
Reiterated
2026-08-06 · TD Cowen reiterated Hold on PODD
Reiterated
2026-08-06 · UBS reiterated Neutral on PODD

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-23 23:44:30 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026